Followers | 127 |
Posts | 4599 |
Boards Moderated | 0 |
Alias Born | 10/20/2001 |
Friday, August 30, 2019 6:30:34 AM
H.C. Wainwright & Co. is one of the country’s oldest and most trusted financial institutions.
History
H.C. Wainwright & Co. was founded in 1868 at the Union Bank Building in Boston, Massachusetts, located at the heart of the strongest financial center in post-Civil War America. Housed at 40 State Street in the same building as the Boston Stock Exchange, H.C. Wainwright & Co. had the advantage of crafting each line of business in-step with the financial landscape of the time. Furthermore, the firm’s location on State Street, where the activities of a thriving merchant port converged with the commerce of downtown Boston, provided a cutting-edge environment for experience and growth. Quickly becoming a prominent and respected member of the Exchange, H.C. Wainwright & Co.’s values of discipline, trust, and client stewardship set the company on a distinctly reputable trajectory towards financial stability and dependability.
Establishing a strong reputation as a proven intendant of client accounts, steadfast fiduciary, and validated bedrock of American finance, H.C. Wainwright & Co. moved deliberately to expand and progress as the contours of modern finance became increasingly complex to navigate. While many other firms struggled, H.C. Wainwright & Co. not only maintained stability, but also grew to transcend the limits of what was expected of the financial community.
Known from our inception as an honest, calculable, and reliable financial services firm, H.C. Wainwright & Co. is prepared and proud to be at our clients’ side for generations to come. The values first instilled in us on State Street have never waivered and we continue to build upon our legacy of service in our new headquarters in New York City. Staffed by a diverse group of seasoned financiers, advisors, and researchers, H.C. Wainwright & Co. blends traditional values with innovative services, operating with care and integrity while offering leading-edge investment banking, corporate finance, and strategic advisory services to public and private growth companies across multiple sectors and regions. MBD
Recent TENX News
- Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study” • GlobeNewswire Inc. • 04/09/2024 12:30:00 PM
- Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 12:30:00 PM
- Tenax Therapeutics to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/12/2024 12:30:00 PM
- Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024 • GlobeNewswire Inc. • 02/29/2024 02:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/26/2024 09:31:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:30:34 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/20/2024 09:01:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 01:33:49 PM
- Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan • GlobeNewswire Inc. • 02/20/2024 01:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/16/2024 04:28:52 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/16/2024 12:36:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:46:29 PM
- Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering • GlobeNewswire Inc. • 02/08/2024 01:16:41 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/08/2024 05:15:17 AM
- Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) • GlobeNewswire Inc. • 02/08/2024 01:01:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:56:32 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM